Jan Terje Andersen

Jan Terje Andersen

Auto-generated profile, based on publicly available information

Jan Terje Andersen

Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
MPMichal Pyzik
Michal Pyzik
KSKine M. K. Sand
Kine M. K. Sand
JHJonathan J. Hubbard
Jonathan J. Hubbard
JAJan Terje Andersen
Jan Terje Andersen
ISInger Sandlie
Inger Sandlie
RBRichard S. Blumberg
Richard S. Blumberg
Antibodies are essential components of an adaptive immune response. Immunoglobulin G (IgG) is the most common type of antibody found in circulation and extracellular fluids. Although IgG alone can directly protect the body from infection through the activities of its antigen binding region, the majority of IgG immune functions are mediated via proteins and receptors expressed by specialized cell subsets that bind to the fragment crystallizable (Fc) region of IgG. Fc gamma (γ) receptors (FcγR) belong to a broad family of proteins that presently include classical membrane-bound surface receptors as well as atypical intracellular receptors and cytoplasmic glycoproteins. Among the atypical FcγRs, the neonatal Fc receptor (FcRn) has increasingly gained notoriety given its intimate influence on IgG biology and its ability to also bind to albumin. FcRn functions as a recycling or transcytosis receptor that is responsible for maintaining IgG and albumin in the circulation, and bidirectionally transporting these two ligands across polarized cellular barriers. More recently, it has been appreciated that FcRn acts as an immune receptor by interacting with and facilitating antigen presentation of peptides derived from IgG immune complexes (IC). Here we review FcRn biology and focus on newer advances including how emerging FcRn-targeted therapies may affect the immune responses to IgG and IgG IC.

8 July 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SQShuo-Wang Qiao
Shuo-Wang Qiao
KKKanna Kobayashi
Kanna Kobayashi
FJFinn-Eirik Johansen
Finn-Eirik Johansen
LSLudvig M. Sollid
Ludvig M. Sollid
JAJan Terje Andersen
Jan Terje Andersen
RBRichard S. Blumberg
Richard S. Blumberg
The neonatal Fc receptor for IgG (FcRn) is a distant member of the MHC class I protein family. It binds IgG and albumin in a pH-dependent manner and protects these from catabolism by diverting them from a degradative fate in lysosomes. In addition, FcRn-mediated IgG transport across epithelial barriers is responsible for the transmission of IgG from mother to infant and can also enhance IgG-mediated antigen uptake across mucosal epithelia. We now show a previously undescribed role for FcRn in mediating the presentation of antigens by dendritic cells when antigens are present as a complex with antibody by uniquely directing multimeric immune complexes, but not monomeric IgG, to lysosomes.

1 September 2011 in Nature Communications
Verified
Journal Article
Open access
NSNigel M. Stapleton
Nigel M. Stapleton
JAJan Terje Andersen
Jan Terje Andersen
ASAnnette M. Stemerding
Annette M. Stemerding
SBStefania P. Bjarnarson
Stefania P. Bjarnarson
RVRuurd C. Verheul
Ruurd C. Verheul
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
Human IgG3 displays the strongest effector functions of all IgG subclasses but has a short half-life for unresolved reasons. Here we show that IgG3 binds to IgG-salvage receptor (FcRn), but that FcRn-mediated transport and rescue of IgG3 is inhibited in the presence of IgG1 due to intracellular competition between IgG1 and IgG3. We reveal that this occurs because of a single amino acid difference at position 435, where IgG3 has an arginine instead of the histidine found in all other IgG subclasses. While the presence of R435 in IgG increases binding to FcRn at neutral pH, it decreases binding at acidic pH, affecting the rescue efficiency-but only in the presence of H435-IgG. Importantly, we show that in humans the half-life of the H435-containing IgG3 allotype is comparable to IgG1. H435-IgG3 also gave enhanced protection against a pneumococcal challenge in mice, demonstrating H435-IgG3 to be a candidate for monoclonal antibody therapies.

26 January 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KSKine Marita Knudsen Sand
Kine Marita Knudsen Sand
MBMalin Bern
Malin Bern
JNJeannette Nilsen
Jeannette Nilsen
HNHanna Theodora Noordzij
Hanna Theodora Noordzij
ISInger Sandlie
Inger Sandlie
JAJan Terje Andersen
Jan Terje Andersen
The neonatal Fc receptor (FcRn) was first found to be responsible for transporting antibodies of the immunoglobulin G (IgG) class from the mother to the fetus or neonate as well as for protecting IgG from intracellular catabolism. However, it has now become apparent that the same receptor also binds albumin and plays a fundamental role in homeostatic regulation of both IgG and albumin, as FcRn is expressed in many different cell types and organs at diverse body sites. Thus, to gain a complete understanding of the biological function of each ligand, and also their distribution in the body, an in-depth characterization of how FcRn binds and regulates the transport of both ligands is necessary. Importantly, such knowledge is also relevant when developing new drugs, as IgG and albumin are increasingly utilized in therapy. This review discusses our current structural and biological understanding of the relationship between FcRn and its ligands, with a particular focus on albumin and design of albumin-based therapeutics.

31 May 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KBKristi Baker
Kristi Baker
SQShuo-Wang Qiao
Shuo-Wang Qiao
TKTimothy T. Kuo
Timothy T. Kuo
VAVictoria G. Aveson
Victoria G. Aveson
BPBarbara Platzer
Barbara Platzer
RBRichard S. Blumberg
Richard S. Blumberg
Cross-presentation of IgG-containing immune complexes (ICs) is an important means by which dendritic cells (DCs) activate CD8+T cells, yet it proceeds by an incompletely understood mechanism. We show that monocyte-derived CD8−CD11b+DCs require the neonatal Fc receptor for IgG (FcRn) to conduct cross-presentation of IgG ICs. Consequently, in the absence of FcRn, Fcγ receptor (FcγR)-mediated antigen uptake fails to initiate cross-presentation. FcRn is shown to regulate the intracellular sorting of IgG ICs to the proper destination for such cross-presentation to occur. We demonstrate that FcRn traps antigen and protects it from degradation within an acidic loading compartment in association with the rapid recruitment of key components of the phagosome-to-cytosol cross-presentation machinery. This unique mechanism thus enables cross-presentation to evolve from an atypically acidic loading compartment. FcRn-driven cross-presentation is further shown to control cross-priming of CD8+T-cell responses in vivo such that during chronic inflammation, FcRn deficiency results in inadequate induction of CD8+T cells. These studies thus demonstrate that cross-presentation in CD8−CD11b+DCs requires a two-step mechanism that involves FcγR-mediated internalization and FcRn-directed intracellular sorting of IgG ICs. Given the centrality of FcRn in controlling cross-presentation, these studies lay the foundation for a unique means to therapeutically manipulate CD8+T-cell responses.

14 January 2019 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
ASAlan Shaw
Alan Shaw
IHIan T. Hoffecker
Ian T. Hoffecker
ISIoanna Smyrlaki
Ioanna Smyrlaki
JRJoao Rosa
Joao Rosa
AGAlgirdas Grevys
Algirdas Grevys
BHBjörn Högberg
Björn Högberg